Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Monopar Advances ALXN1840 with Rolling NDA and Positive Wilson Data

Aug 12, 2026, 9:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term regulatory catalysts (rolling NDA, RPD PRV) and positive trial signals could lift MNPR from current levels, conditional on regulatory success and timing.

AI summary

What happened, with direct paths to the underlying reporting

Monopar reported Q2 2026 results and highlighted ALXN1840 progress, including a rolling NDA submission and FDA Rare Pediatric Disease designation. Phase 3 FoCus analyses showed superior neurologic benefit versus standard of care, supporting an approval pathway. The company also expanded its commercial leadership and held $134.3 million in cash, funding operations into 2027.

Rolling NDA for ALXN1840 initiated; submission anticipated in months.
FDA Rare Pediatric Disease designation granted; potential PRV value.
Q2 2026 cash $134.3M; runway through 12/31/2027.
Q2 2026 net loss $5.3M; R&D expense rose to $4.77M.
Phase 3 FoCus shows greater neurologic benefit vs standard of care.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Monopar Advances ALXN1840 with Rolling NDA and Positive Wilson Data

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?